Skip to Content

Differences in HbA1c do not explain cardiovascular benefits in the treatment of type 2 diabetes

Treatment that reduce the hyperglycemic burden in patients with tye 2 diabetes reduce the risk of microvascular complications – as retinopathy, nephropathy and neuropathy. But where are the link to the cardiovascular protection we have seen in the treatment of type 2 diabetes with SGLT-2 inhibitor and GLP-1 receptor agonists. In this MEDtalk you will get an answer from Odd Erik Johansen, Bærum Hospital, Oslo University Hospital.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top